Advitech announces positive results in wound healing


    QUEBEC CITY, May 7 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) announces today new in vivo data
from its R&D wound healing program confirming once again the potential of the
IM technology platform for wound healing applications.
    These data demonstrate two distinct effects of the IM fraction on wound
healing. First, the IM fraction induces significant tissue ingrowth leading to
an accelerated wound healing process. Tissue ingrowth was increased 2-fold
compared with the neutral proteins control (P=0.001). Secondly, the IM
fraction reduces scar formation and prevents hypertrophic scarring. This
bioactivity appears to be associated with the presence of growth factors and
peptides with immune modulatory properties as well as antimicrobial
    "These new data once again confirm the potential of IM platform to
improve the wound healing process as well as scar remodelling. The bioactive
properties of the IM platform suggest that once incorporated as a bioactive
compound in a matrix or implant, the IM platform might accelerate the natural
process of wound healing for burned patients or for other patients undergoing
various surgeries." said Dr Charles Doillon, M.D., Ph.D., researcher at Centre
de Recherche du Centre Hospitalier de l'Université Laval who is leading this
    In 2008, Advitech has put in place an extensive R&D wound healing program
to characterize specific fractions and to obtain toxicological data through in
vitro and in vivo studies.
    Wound healing does represent a significant opportunity for Advitech and
should help the Corporation to rapidly diversify its products portfolio and
this, ideally, in both pharmaceutical and cosmeceutical sectors.


    According to Epsicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. The market
growth is fueled by the population ageing, the increased incidence of diabetes
as well as the technological advancement and the introduction of more
efficient and cost-effective therapies compared to conventional treatments.


    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has initiated an innovative wound healing research program to
develop new applications for both its XP-828L and IM technological platforms.

    This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF

For further information:

For further information: Advitech Inc.: Renaud Beauchesne, MBA,
Executive Chairman, (418) 686-7498, ext. 228,; Serge Comeau,
Investor's relations, (514) 862-4160,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890